Arcturus Therapeutics (ARCT) Gets a Sell Rating from B.Riley Financial
B.Riley Financial analyst Mayank Mamtani reiterated a Sell rating on Arcturus Therapeutics (ARCT) today and set a price target of $23.00. The company’s shares closed last Tuesday at $27.23, close to its 52-week low of $25.22.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 21.1% and a 46.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Arcturus Therapeutics with a $37.75 average price target.
See today’s analyst top recommended stocks >>
Based on Arcturus Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 million and GAAP net loss of $31.1 million. In comparison, last year the company earned revenue of $2.97 million and had a GAAP net loss of $10.99 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.